Prexasertib dihydrochloride (LY2606368 dihydrochloride) 是一种选择性的,ATP 竞争性的第二代细胞周期检测点激酶 1 (CHK1) 抑制剂,Ki为 0.9 nM,IC50为<1 nm。prexasertib dihydrochloride 抑制 CHK2 (IC50=8 nM) 和 RSK1 (IC50=9 nM)。Prexasertib dihydrochloride 引起双链 DNA 断裂和复制突变,导致细胞凋亡 (apoptosis)。Prexasertib dihydrochloride 显示有效的抗肿瘤活性。
生物活性 | Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generationcheckpoint kinase 1 (CHK1)inhibitor with aKiof 0.9 nM and anIC50of<1 nm. prexasertib dihydrochloride inhibitsCHK2(IC50=8 nM) andRSK1(IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting inapoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity[1][2]. |
IC50& Target[1] | Chk1 <1 nM (IC50) | Chk2 8 nM (IC50) | Chk1 0.9 nM (Ki) |
|
体外研究 (In Vitro) | Prexasertib dihydrochloride (LY2606368 dihydrochloride) inhibits MELK (IC50=38 nM), SIK (IC50=42 nM), BRSK2 (IC50=48 nM), ARK5 (IC50=64 nM). LY2606368 requires CDC25A and CDK2 to cause DNA damage[1]. Prexasertib dihydrochloride (33, 100 nM; for 7 hours) results in DNA damage during S-phase in HeLa cells[1]. Prexasertib dihydrochloride (8-250 nM; pre-treated for 15 minutes) inhibits CHK1 autophosphorylation (S296) and CHK2 autophosphorylation (S516) in HT-29 cells[1]. Prexasertib dihydrochloride (4 nM; 24 hours) results in a large shift in cell-cycle populations from G1 and G2-M to S-phase with an accompanied induction of H2AX phosphorylation in U-2 OS cells[1]. Prexasertib dihydrochloride (33 nM; for 12 hours) causes chromosomal fragmentation in HeLa cells. Prexasertib (100 nM; 0.5 to 9 hours) induces replication stress and depletes the pool of available RPA2 for binding to DNA[1].
Cell Cycle Analysis[1] Cell Line: | HeLa cells | Concentration: | 33, 100 nM | Incubation Time: | For 7 hours | Result: | Had an IC50of 37 nM and resulted in the G2-M population received DNA damage during S-phase but continued to progress through the cell cycle into an early mitosis. |
Western Blot Analysis[1] Cell Line: | HT-29 cells | Concentration: | 8, 16, 31, 63, 125, 250 nM | Incubation Time: | Pre-treated for 15 minutes | Result: | Inhibited CHK1 autophosphorylation (S296) and CHK2 autophosphorylation (S516) (IC50of less than 31 nM) in HT-29 cells. |
|
体内研究 (In Vivo) | Prexasertib dihydrochloride (LY2606368 dihydrochloride; 1-10 mg/kg; SC; twice daily for 3 days, rest 4 days; for three cycles) causes growth inhibition in tumor xenografts[1]. Prexasertib dihydrochloride (15 mg/kg; SC) causes CHK1 inhibition in the blood and the phosphorylation of both H2AX (S139) and RPA2 (S4/S8)[1].
Animal Model: | Female CD-1 nu-/nu- mice (26-28 g) with Calu-6 cells[1] | Dosage: | 1, 3.3, or 10 mg/kg | Administration: | SC; twice daily for 3 days, rest 4 days; for three cycles | Result: | Caused statistically significant tumor growth inhibition (up to 72.3%). |
Animal Model: | Female CD-1 nu-/nu- mice (26-28 g) with Calu-6 cells[1] | Dosage: | 15 mg/kg (Pharmacokinetic Analysis) | Administration: | SC (200 μL) | Result: | CHK1 was 7 ng/mL at 12 hours and 3 ng/mL by 24 hours in plasma exposures. Phosphorylation of both H2AX (S139) and RPA2 (S4/S8) was detectable at 4 hours, showing the rapid occurrence of DNA damage. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 8 mg/mL(18.25 mM;Need ultrasonic) H2O : 1 mg/mL(2.28 mM;ultrasonic and warming and heat to 80℃) 配制储备液 1 mM | 2.2815 mL | 11.4075 mL | 22.8149 mL | 5 mM | 0.4563 mL | 2.2815 mL | 4.5630 mL | 10 mM | 0.2281 mL | 1.1407 mL | 2.2815 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 0.8 mg/mL (1.83 mM); Clear solution
此方案可获得 ≥ 0.8 mg/mL (1.83 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 8.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 0.8 mg/mL (1.83 mM); Clear solution
此方案可获得 ≥ 0.8 mg/mL (1.83 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 8.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|